rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-532-538rsp-3815Research ArticleИНФОРМАЦИЯINFORMATION16-й Международный конгресс по системной красной волчанке (LUPUS 2025)Participation in the 16th International congress on systemic lupus erythematosus (LUPUS 2025)https://orcid.org/0000-0003-1318-1894ШумиловаА. А.ShumilovaA. A.

Шумилова Анастасия Александровна 

115522, Москва, Каширское шоссе, 34а

Anastasiia A. Shumilova 

115522, Moscow, Kashirskoye Highway, 34A

dr.anashumilova@gmail.comФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202501112025635532538Copyright © Шумилова А.А., 20252025Шумилова А.А.Shumilova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3815

На конгрессе LUPUS 2025 были представлены новейшие данные по системной красной волчанке (СКВ): обновлен алгоритм терапии кожных форм, для волчаночного нефрита предложена ранняя тройная схема терапии и сделан акцент на стандартизированные гистологические критерии ответа. Выделены новые биомаркеры, использование которых позволяет улучшить стратификацию больных. Представлен консенсусный проект рекомендаций по терапии 24 редких проявлений СКВ.

The LUPUS 2025 Congress showcased cutting-edge data on systemic lupus erythematosus (SLE). Highlights included an updated step-wise treatment algorithm for cutaneous lupus, the proposal of an early triple-therapy regimen for lupus nephritis with standardized histologic response criteria, and the identification of novel biomarkers that enhance patient stratification. In addition, an expert consensus provided therapeutic guidance for 24 rare SLE manifestations.

системная красная волчанкаволчаночный нефритантифосфолипидный синдромбиомаркерыsystemic lupus erythematosuslupus nephritisantiphospholipid syndromebiomarkersСтатья подготовлена в рамках темы ФГБНУ НИИР им. В.А. Насоновой РК 125020501434-1.ReferencesFanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910-926. doi: 10.1016/j.ard.2025.02.023Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910-926. doi: 10.1016/j.ard.2025.02.023Khosravi-Hafshejani T, On A, Ali H, Chambers S, Yang X, Almeida Gomes LL, et al. The patterns of recurrence in cutaneous lupus erythematosus: A retrospective analysis of SCLE and DLE flares. J Am Acad Dermatol. 2025;93(4):1125-1126. doi: 10.1016/j.jaad.2025.06.025Khosravi-Hafshejani T, On A, Ali H, Chambers S, Yang X, Almeida Gomes LL, et al. The patterns of recurrence in cutaneous lupus erythematosus: A retrospective analysis of SCLE and DLE flares. J Am Acad Dermatol. 2025;93(4):1125-1126. doi: 10.1016/j.jaad.2025.06.025Furie R, Werth VP, Milliman E, Ferber K, Brown R, Zoghbi J, et al. Pharmacodynamic effects of litifilimab in lupus in the LILAC phase II study: Rapid and sustained reductions in type I interferon-associated gene expression and cytokines. Arthrit Rheumatol. 2025 Jun 9. doi: 10.1002/art.43271Furie R, Werth VP, Milliman E, Ferber K, Brown R, Zoghbi J, et al. Pharmacodynamic effects of litifilimab in lupus in the LILAC phase II study: Rapid and sustained reductions in type I interferon-associated gene expression and cytokines. Arthrit Rheumatol. 2025 Jun 9. doi: 10.1002/art.43271Pearson D, Morand E, Wenzel J, Furie R, Dall’Era M, Sanchez-Guerrero J, et al. Randomized, placebo-controlled phase II study of enpatoran, a small molecule Toll-like receptor 7/8 inhibitor, in cutaneous lupus erythematosus: Results from cohort A. J Rheumatol. 2025;52(Suppl 1):11.1-11. doi: 10.3899/jrheum.2025-0390.O010Pearson D, Morand E, Wenzel J, Furie R, Dall’Era M, SanchezGuerrero J, et al. Randomized, placebo-controlled phase II study of enpatoran, a small molecule Toll-like receptor 7/8 inhibitor, in cutaneous lupus erythematosus: Results from cohort A. J Rheumatol. 2025;52(Suppl 1):11.1-11. doi: 10.3899/jrheum.2025-0390.O010McDonald KA, Lytvyn Y, Mufti A, Chan AW, Rosen CF. Review on photoprotection: A clinician’s guide to the ingredients, characteristics, adverse effects, and disease-specific benefits of chemical and physical sunscreen compounds. Arch Dermatol Res. 2022;315(4):735-749. doi: 10.1007/s00403-022-02483-4McDonald KA, Lytvyn Y, Mufti A, Chan AW, Rosen CF. Review on photoprotection: A clinician’s guide to the ingredients, characteristics, adverse effects, and disease-specific benefits of chemical and physical sunscreen compounds. Arch Dermatol Res. 2022;315(4):735-749. doi: 10.1007/s00403-022-02483-4Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, Duarte-García A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthrit Rheumatol. 2025;77(9):1115-1135. doi: 10.1002/art.43212Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, DuarteGarcía A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthrit Rheumatol. 2025;77(9):1115-1135. doi: 10.1002/art.43212Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Floege J. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(1):S1-69. doi: 10.1016/j.kint.2023.09.002Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Floege J. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(1):S1-69. doi: 10.1016/j.kint.2023.09.002Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2021; 397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-XRovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, RomeroDiaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2021; 397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-XFurie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martínez G, Zuta Santillán AE, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471-1483. doi: 10.1056/NEJMoa2410965Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martínez G, Zuta Santillán AE, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471-1483. doi: 10.1056/NEJMoa2410965Rossi GM, Vaglio A. New treatment regimens, new drugs, and new treatment goals for lupus nephritis. J Clin Med. 2025;14(2):584. doi: 10.3390/jcm14020584Rossi GM, Vaglio A. New treatment regimens, new drugs, and new treatment goals for lupus nephritis. J Clin Med. 2025;14(2):584. doi: 10.3390/jcm14020584Parodis I, Cetrez N, Palazzo L, Alberton V, Anders HJ, Bajema IM, et al. Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: A systematic literature review-based proposal. Autoimmun Rev. 2025;24(7):103810. doi: 10.1016/j.autrev.2025.103810Parodis I, Cetrez N, Palazzo L, Alberton V, Anders HJ, Bajema IM, et al. Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: A systematic literature review-based proposal. Autoimmun Rev. 2025;24(7):103810. doi: 10.1016/j.autrev.2025.103810Burns G, Legge A. Developing and evaluating a laboratory-based frailty index (FI-LAB) for the prediction of long-term health outcomes in systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):13-14. doi: 10.3899/jrheum.2025-0390.O013Burns G, Legge A. Developing and evaluating a laboratory-based frailty index (FI-LAB) for the prediction of long-term health outcomes in systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):13-14. doi: 10.3899/jrheum.2025-0390.O013Pasternak E, Freud T, Press Y. Association between the frailty index based on laboratory tests and all-cause mortality in hospitalized older adults: Retrospective cohort study. JMIR Aging. 2025;8:e70204. doi: 10.2196/70204Pasternak E, Freud T, Press Y. Association between the frailty index based on laboratory tests and all-cause mortality in hospitalized older adults: Retrospective cohort study. JMIR Aging. 2025;8:e70204. doi: 10.2196/70204Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412Nosal RS, Superville SS, Amraei R, Varacallo MA. Biochemistry, antinuclear antibodies (ANA). 2022 Dec 29. Treasure Island (FL):StatPearls Publishing;2025.Nosal RS, Superville SS, Amraei R, Varacallo MA. Biochemistry, antinuclear antibodies (ANA). 2022 Dec 29. Treasure Island (FL):StatPearls Publishing;2025.Tešija Kuna A, Đerek L, Drvar V, Kozmar A, Gugo K. Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb). 2021;31(2):210-229. doi: 10.11613/BM.2021.020502Tešija Kuna A, Đerek L, Drvar V, Kozmar A, Gugo K. Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb). 2021;31(2):210-229. doi: 10.11613/BM.2021.020502Fritzler MJ, Choi MY. Antinuclear antibody testing: Gold standard revisited. J Appl Lab Med. 2022;7(1):357-361. doi: 10.1093/jalm/jfab129Fritzler MJ, Choi MY. Antinuclear antibody testing: Gold standard revisited. J Appl Lab Med. 2022;7(1):357-361. doi: 10.1093/jalm/jfab129Zhan K, Buhler KA, Chen IY, Fritzler MJ, Choi MY. Systemic lupus in the era of machine learning medicine. Lupus Sci Med. 2024;11(1):e001140. doi: 10.1136/lupus-2023-001140Zhan K, Buhler KA, Chen IY, Fritzler MJ, Choi MY. Systemic lupus in the era of machine learning medicine. Lupus Sci Med. 2024;11(1):e001140. doi: 10.1136/lupus-2023-001140Moghaddam F, Sajadi J, Clarke A, Bernatsky S, Costenbader K, Chen I, et al. Rheumatology diagnostics utilizing artificial intelligence for ANA pattern identification and titre quantification. J Rheumatol. 2025;52(Suppl 1):71.2-72. doi: 10.3899/jrheum.2025-0390.PT012Moghaddam F, Sajadi J, Clarke A, Bernatsky S, Costenbader K, Chen I, et al. Rheumatology diagnostics utilizing artificial intelligence for ANA pattern identification and titre quantification. J Rheumatol. 2025;52(Suppl 1):71.2-72. doi: 10.3899/jrheum.2025-0390.PT012Raeber ME, Caspar DP, Zurbuchen Y, Guo N, Schmid J, Michler J, et al. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity. 2024;57(9):2232-2250.e10. doi: 10.1016/j.immuni.2024.07.016Raeber ME, Caspar DP, Zurbuchen Y, Guo N, Schmid J, Michler J, et al. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity. 2024;57(9):2232-2250.e10. doi: 10.1016/j.immuni.2024.07.016Smith J, Whittall-Garcia L, Bonilla D, Li Q, Wither J, Gladman DD, et al. Type I interferon status and clinical manifestations in a large cohort of patients with systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):99.1-99. doi: 10.3899/jrheum.2025-0390.PV036Smith J, Whittall-Garcia L, Bonilla D, Li Q, Wither J, Gladman DD, et al. Type I interferon status and clinical manifestations in a large cohort of patients with systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):99.1-99. doi: 10.3899/jrheum.2025-0390.PV036Panafidina T, Popkova T, Shumilova A, Gorbunova Y, Kondrateva L, Tchetina E, et al. Effect of comorbidity and standard therapy on interferon status in patients with systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):98.2-99. doi: 10.3899/jrheum.2025-0390.PV035Panafidina T, Popkova T, Shumilova A, Gorbunova Y, Kondrateva L, Tchetina E, et al. Effect of comorbidity and standard therapy on interferon status in patients with systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):98.2-99. doi: 10.3899/jrheum.2025-0390.PV035Panafidina T, Popkova T, Shumilova A, Gorbunova Y, Kondrateva L, Tchetina E, et al. Clinical significance of interferon status in patients with systemic lupus erythematosus: Preliminary data. J Rheumatol. 2025;52(Suppl 1):202.1-202. doi: 10.3899/jrheum.2025-0390.PV196Panafidina T, Popkova T, Shumilova A, Gorbunova Y, Kondrateva L, Tchetina E, et al. Clinical significance of interferon status in patients with systemic lupus erythematosus: Preliminary data. J Rheumatol. 2025;52(Suppl 1):202.1-202. doi: 10.3899/jrheum.2025-0390.PV196Costa R, Guaraná W, Júnior B, Clementino J, Da Costa Neto J, Inês L, et al. Does SLEDAI-2K reflect the interferon-alpha gene signature in systemic lupus erythematosus? Preliminary results from a cohort. J Rheumatol. 2025;52(Suppl 1):139.1-139. doi: 10.3899/jrheum.2025-0390.PV103Costa R, Guaraná W, Júnior B, Clementino J, Da Costa Neto J, Inês L, et al. Does SLEDAI-2K reflect the interferon-alpha gene signature in systemic lupus erythematosus? Preliminary results from a cohort. J Rheumatol. 2025;52(Suppl 1):139.1-139. doi: 10.3899/jrheum.2025-0390.PV103Costa R, Guaraná W, Júnior B, Pedroza L, Inês L, Sandrin-Garcia P, et al. Ophthalmic involvement in systemic lupus erythematosus is associated with interferon-alpha gene signature: A cross-sectional study. J Rheumatol. 2025;52(Suppl 1):138.2-138. doi: 10.3899/jrheum.2025-0390.PV102Costa R, Guaraná W, Júnior B, Pedroza L, Inês L, Sandrin-Garcia P, et al. Ophthalmic involvement in systemic lupus erythematosus is associated with interferon-alpha gene signature: A cross-sectional study. J Rheumatol. 2025;52(Suppl 1):138.2-138. doi: 10.3899/jrheum.2025-0390.PV102Liu Y, Li M, Zhang H, Yin Z, Wang X. Clinical significance of serum soluble scavenger receptor CD163 in patients with lupus nephritis. Lupus. 2024;33(12):1279-1288. doi: 10.1177/09612033241276033Liu Y, Li M, Zhang H, Yin Z, Wang X. Clinical significance of serum soluble scavenger receptor CD163 in patients with lupus nephritis. Lupus. 2024;33(12):1279-1288. doi: 10.1177/09612033241276033Li M, Barreth N, Cheema K, Muruve D, Pierre Y St., Clarke A, et al. Novel urinary biomarker model for differentiating lupus nephritis from ANCA-associated vasculitis. J Rheumatol. 2025;52(Suppl 1):151.2-152. doi: 10.3899/jrheum.2025-0390.PV126Li M, Barreth N, Cheema K, Muruve D, Pierre Y St., Clarke A, et al. Novel urinary biomarker model for differentiating lupus nephritis from ANCA-associated vasculitis. J Rheumatol. 2025;52(Suppl 1):151.2-152. doi: 10.3899/jrheum.2025-0390.PV126Lindblom J, Beretta L, Borghi MO, Alarcón-Riquelme ME, Parodis I. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. Front Immunol. 2023;14:1257085. doi: 10.3389/fimmu.2023.1257085Lindblom J, Beretta L, Borghi MO, Alarcón-Riquelme ME, Parodis I. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. Front Immunol. 2023;14:1257085. doi: 10.3389/fimmu.2023.1257085Parodis I, Lagutkin D, Lindblom J, Idborg H, Beretta L, Borghi MO, et al. New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity – could anti-LIN28A enhance precision in diagnostics? Ann Rheum Dis. 2025;84(7):1180-1194. doi: 10.1016/j.ard.2025.04.003Parodis I, Lagutkin D, Lindblom J, Idborg H, Beretta L, Borghi MO, et al. New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity – could anti-LIN28A enhance precision in diagnostics? Ann Rheum Dis. 2025;84(7):1180-1194. doi: 10.1016/j.ard.2025.04.003Arnold J, Carter LM, Md Yusof MY, Dutton K, Wigston Z, Dass S, et al. ANA-associated arthritis: Clinical and biomarker characterization of a population for basket trials. Rheumatology. 2024;63(11):3135-3145. doi: 10.1093/rheumatology/keae269Arnold J, Carter LM, Md Yusof MY, Dutton K, Wigston Z, Dass S, et al. ANA-associated arthritis: Clinical and biomarker characterization of a population for basket trials. Rheumatology. 2024;63(11):3135-3145. doi: 10.1093/rheumatology/keae269Arnold J, Carter LM, Yusof MYM, Wigston Z, Dominguez DT, Barturen G, et al. Discovery and validation of a new classification of ANA-RMDS that better predict long-term outcomes compared to legacy diagnoses. J Rheumatol. 2025;52(Suppl 1):15-16. doi: 10.3899/jrheum.2025-0390.O015Arnold J, Carter LM, Yusof MYM, Wigston Z, Dominguez DT, Barturen G, et al. Discovery and validation of a new classification of ANA-RMDS that better predict long-term outcomes compared to legacy diagnoses. J Rheumatol. 2025;52(Suppl 1):15-16. doi: 10.3899/jrheum.2025-0390.O015Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall’Era M, Adelowo O, et al. ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol. 2025;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall’Era M, Adelowo O, et al. ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol. 2025;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, et al. Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): Results of a prospective, single-arm, open-label, phase 2 trial. Ann Rheum Dis. 2025;84(6):1011-1022. doi: 10.1016/j.ard.2025.02.012Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, et al. Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): Results of a prospective, single-arm, open-label, phase 2 trial. Ann Rheum Dis. 2025;84(6):1011-1022. doi: 10.1016/j.ard.2025.02.012

The authors declare that there are no conflicts of interest present.